在丹麦，对于2型糖尿病，Semaglutide + metformin与恩格列净+ metformin相比没有成本效益

{"title":"在丹麦，对于2型糖尿病，Semaglutide + metformin与恩格列净+ metformin相比没有成本效益","authors":"A. cost-utility","doi":"10.1007/s40274-021-08254-8","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":19781,"journal":{"name":"PharmacoEconomics & Outcomes News","volume":"4 1","pages":"23 - 23"},"PeriodicalIF":0.0000,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Semaglutide + metformin not cost effective vs empagliflozin + metformin for T2DM in Denmark\",\"authors\":\"A. cost-utility\",\"doi\":\"10.1007/s40274-021-08254-8\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":19781,\"journal\":{\"name\":\"PharmacoEconomics & Outcomes News\",\"volume\":\"4 1\",\"pages\":\"23 - 23\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"PharmacoEconomics & Outcomes News\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s40274-021-08254-8\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"PharmacoEconomics & Outcomes News","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s40274-021-08254-8","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}